cagrilintide news 2025 Structural and dynamic features of binding to calcitonin and amylin receptors In the REDEFINE 2 phase
In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Efficacy and safety of co administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised Updates in Medicine REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio Phase 3a RCT in 1206 adults with T2D (BMI 27, HbA1c 710%) Instagram CagriSema (CagrilintideSemaglutide) in Adults with Overweight or Obesity and Type 2 Diabetes Headlands Research Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Acta Pharmacologica Sinica
Pay in 4 interest-free payments of $6.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23

00402-4/asset/7d856d37-1b1d-4481-9723-c6f28077488d/main.assets/gr2_lrg.jpg)

